Core Insights - Inspire Medical Systems, Inc. is facing a class action lawsuit for allegedly misleading investors regarding the launch of its Inspire V Device, which was anticipated to significantly increase revenue [1][5] - The lawsuit highlights operational failures, including insufficient training for treatment centers and IT system issues, leading to a more than 80% reduction in the company's 2025 earnings guidance [2][5] - Following the earnings guidance cut, the stock price plummeted over 32%, resulting in a loss of $1.2 billion in market capitalization [2] Financial Performance - The company's stock has shown considerable volatility, with a 52-week high of $216.01 and a low of $70.77 [4] - As of the latest trading, the stock is priced at $125.22, despite a recent decrease of 1.66%, equating to a $2.11 drop [3][5] - Wolfe Research upgraded Inspire's stock to "Outperform" on November 25, 2025, indicating potential for recovery [3][5] Market Position - Inspire Medical Systems has a current market capitalization of approximately $3.71 billion, with a trading volume of 508,655 shares [4] - Shareholders interested in the class action lawsuit must submit their papers by January 5, 2026, with Robbins LLP managing the case on a contingency fee basis [4]